Asma Siari,
Technology and Market Analyst,
Yole Développement
Asma Siari is a Technology & Market Analyst in Life Sciences & Healthcare Division at Yole Développement. She is involved in the development of technology & market reports as well as the production of custom consulting projects. After a Master’s degree in Biotechnologies, Diagnostic therapeutics & Management, Asma serves as Research Assistant at the Moores Cancer Center (San Diego, CA). She is a coauthor in two scientific publications published in the Molecular Cancer Research Journal. In addition to her mission at Yole, Asma is graduated recently with an Advanced Master’s degree in International Strategy & Marketing BtoB (EM Lyon Business School, France).
Point of Need Testing & Liquid Biopsy Technology & Market Overview: Challenges, Market Trends and New Solutions
Tuesday, 5 June 2018 at 17:00
Add to Calendar ▼2018-06-05 17:00:002018-06-05 18:00:00Europe/LondonPoint of Need Testing and Liquid Biopsy Technology and Market Overview: Challenges, Market Trends and New SolutionsPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
As healthcare becomes more consumer-focused, the need for convenient diagnosis, monitoring, and screening tests is expanding worldwide. Disruptive innovations can substantially change industries and make their products and services cheaper, more accessible and provide benefits for patients. With integration and decentralization of healthcare delivery systems and shift of diagnostics from reference laboratories to locations closer from the patient, Point of Need testing based on microfluidic technologies is gaining ground, making a major impact on the medical practices in recent years. Innovative companies in this market have respond to the unmet need for non-invasive and decentralized testing by undertaking technological approaches to develop diagnostics tests for an array of applications. Liquid biopsy is also an emerging technology enabling a novel approach to cancer testing. Considered as an attractive alternative to invasive and expensive solid biopsies, liquid biopsy tests are helping cancer therapy selection and monitoring. Liquid biopsy testing involves the molecular characterization of analytes such as ctDNA, CTCs, or exosomes, enabling better understanding of cancer mechanisms. However, an extensive validation of these tests in clinical trials is definitely required before they are expected to gain widespread adoption in clinical practice. Yole will provide an overview of these devices, their applications and the challenges that industries will face to commercialize their technologies.
Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors Europe 2018Point-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-06-05 17:00:002018-06-05 18:00:00Europe/LondonPoint of Need Testing and Liquid Biopsy Technology and Market Overview: Challenges, Market Trends and New SolutionsPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
